Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Association Between Immune-related Hub Genes Cd36, Cxcl13, Fgfr4, Gabbr1, Lamp3, Mmp12, And Ppm1h And Colorectal Cancer Prognosis

Association between immune-related hub genes CD36, CXCL13, FGFR4, GABBR1, LAMP3, MMP12, and PPM1H and colorectal cancer prognosis

Liuli Wang1,2, Xiaohua Dong1, Miao Yu2

  • 1The First Clinical Medical College of Lanzhou University Lanzhou 730000, Gansu, China.

American Journal of Translational Research
|February 7, 2024

Related Experiment Videos

Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal
08:00

Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal

Published on: October 11, 2019

7.6K
Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres
06:52

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Published on: July 22, 2020

6.5K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

270

View abstract on PubMed

Summary
This summary is machine-generated.

This study identifies seven immune-related genes to predict colorectal cancer (CRC) prognosis. The developed model accurately differentiates high-risk patients and guides personalized immunotherapy strategies.

Area of Science:

  • Oncology
  • Immunology
  • Bioinformatics

Background:

  • Colorectal cancer (CRC) prognosis remains challenging.
  • Identifying immune-related biomarkers is crucial for personalized treatment.

Purpose of the Study:

  • To identify immune-related prognostic genes in colorectal cancer (CRC).
  • To develop a prognostic risk model for CRC.
  • To explore the role of these genes in CRC progression and immune infiltration.

Main Methods:

  • Integrated bioinformatic analyses to construct a prognostic risk model.
  • Utilized seven gene signatures: CD36, CXCL13, FGFR4, GABBR1, LAMP3, MMP12, and PPM1H.
  • Kaplan-Meier analysis for survival outcome and assessment of immune cell infiltration.

Main Results:

Keywords:
Colorectal cancerimmune cell infiltrationprognostic biomarkerstumor immune microenvironment

Related Experiment Videos

Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal
08:00

Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal

Published on: October 11, 2019

7.6K
Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres
06:52

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Published on: July 22, 2020

6.5K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

270
  • A seven-gene prognostic model accurately predicted CRC patient survival in training and test cohorts.
  • High-risk patients showed worse survival outcomes.
  • Low-risk patients had greater infiltration of M1 macrophages, CD8+ T cells, CD4+ T cells, and activated NK cells.

Conclusions:

  • Seven immune-related hub genes serve as effective signatures for predicting CRC prognosis.
  • The model can differentiate patient benefit for individualized immunotherapy.
  • These findings support the development of targeted immunotherapies for CRC.